Sang-We Kim Selected Research

5- (2,4- dihydroxy- 5- isopropylphenyl)- 4- (4- morpholin- 4- ylmethylphenyl)isoxazole- 3- carboxylic acid ethylamide

7/2022	Integrin αvβ3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non-Small Cell Lung Cancer.
12/2018	HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells.
1/2018	Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.
10/2017	The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
3/2016	The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sang-We Kim Research Topics

Disease

94	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 07/2022 - 07/2002
47	Neoplasms (Cancer) 07/2022 - 12/2003
25	Disease Progression 01/2022 - 12/2003
13	Lung Neoplasms (Lung Cancer) 01/2022 - 07/2012
13	Neoplasm Metastasis (Metastasis) 06/2021 - 07/2002
9	Adenocarcinoma of Lung 01/2021 - 04/2012
8	Exanthema (Rash) 01/2022 - 05/2012
8	Adenocarcinoma 05/2021 - 11/2008
8	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2021 - 10/2007
5	Diarrhea 09/2021 - 12/2012
4	Pneumonia (Pneumonitis) 01/2022 - 12/2003
4	Brain Neoplasms (Brain Tumor) 01/2022 - 09/2009
4	Neutropenia 01/2018 - 10/2007
4	Nausea 01/2017 - 01/2014
3	Stomach Neoplasms (Stomach Cancer) 06/2021 - 05/2013
3	Breast Neoplasms (Breast Cancer) 01/2019 - 02/2005
3	Vomiting 01/2017 - 01/2014
3	Acne Vulgaris 01/2016 - 01/2004
3	Lymphoma (Lymphomas) 01/2016 - 11/2003
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 07/2011 - 08/2010
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 02/2011 - 08/2002
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 01/2019
2	Fatigue 09/2021 - 04/2012
2	Paronychia 09/2021 - 01/2004
2	Sarcoma (Soft Tissue Sarcoma) 09/2020 - 09/2015
2	Epilepsy (Aura) 04/2017 - 04/2016
2	Renal Insufficiency (Renal Failure) 01/2016 - 04/2012
2	Dyspnea (Shortness of Breath) 12/2012 - 12/2003
2	Interstitial Lung Diseases (Interstitial Lung Disease) 04/2012 - 02/2010
2	Multiple Myeloma 02/2011 - 04/2010
2	Pathologic Constriction (Stenosis) 07/2009 - 12/2003
1	Gastritis 01/2022
1	Colorectal Neoplasms (Colorectal Cancer) 01/2022

Drug/Important Bio-Agent (IBA)

34	ErbB Receptors (EGF Receptor)IBA 01/2022 - 01/2004
27	Tyrosine Kinase InhibitorsIBA 01/2022 - 09/2009
22	Gefitinib (Iressa)FDA Link 01/2021 - 01/2004
17	PlatinumIBA 12/2021 - 11/2007
14	osimertinibIBA 01/2022 - 04/2015
14	Pemetrexed (MTA)FDA Link 09/2020 - 06/2011
13	Cisplatin (Platino)FDA LinkGeneric 01/2019 - 07/2003
12	Erlotinib Hydrochloride (CP 358,774)FDA Link 06/2019 - 09/2009
11	Pharmaceutical PreparationsIBA 01/2022 - 05/2012
10	AfatinibIBA 01/2022 - 05/2012
7	NivolumabIBA 01/2022 - 10/2017
6	Carboplatin (JM8)FDA LinkGeneric 01/2020 - 02/2005
6	Gemcitabine FDA Link 04/2012 - 02/2006
5	Proteins (Proteins, Gene)FDA Link 07/2022 - 05/2006
5	5- (2,4- dihydroxy- 5- isopropylphenyl)- 4- (4- morpholin- 4- ylmethylphenyl)isoxazole- 3- carboxylic acid ethylamideIBA 07/2022 - 03/2016
5	Anaplastic Lymphoma KinaseIBA 03/2022 - 09/2015
5	Paclitaxel (Taxol)FDA LinkGeneric 01/2020 - 08/2003
4	Immune Checkpoint InhibitorsIBA 08/2021 - 01/2020
4	CrizotinibIBA 01/2020 - 09/2015
4	Etoposide (VP 16)FDA LinkGeneric 01/2019 - 02/2011
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2011 - 02/2005
3	IpilimumabIBA 01/2022 - 11/2016
3	pembrolizumabIBA 01/2022 - 01/2019
3	LigandsIBA 08/2021 - 07/2012
3	belotecanIBA 01/2021 - 10/2007
3	EnzymesIBA 01/2020 - 01/2016
3	Monoclonal AntibodiesIBA 10/2019 - 02/2017
3	Biomarkers (Surrogate Marker)IBA 01/2019 - 09/2017
3	Docetaxel (Taxotere)FDA Link 08/2015 - 02/2010
3	Bevacizumab (Avastin)FDA Link 06/2011 - 06/2011
3	Doxorubicin (Adriamycin)FDA LinkGeneric 02/2011 - 12/2003
2	Biological ProductsIBA 07/2022 - 01/2022
2	ceritinibIBA 03/2022 - 01/2017
2	B7-H1 AntigenIBA 01/2022 - 11/2019
2	lazertinibIBA 01/2022 - 12/2019
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 04/2017
2	CamptothecinIBA 01/2021 - 01/2010
2	durvalumabIBA 01/2021 - 10/2019
2	Protein Glutamine gamma Glutamyltransferase 2IBA 01/2020 - 01/2019
2	Peptides (Polypeptides)IBA 01/2020 - 01/2019
2	brigatinibIBA 01/2020 - 08/2017
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2019 - 12/2011
2	DNA (Deoxyribonucleic Acid)IBA 12/2017 - 01/2016
2	Alanine Transaminase (SGPT)IBA 11/2017 - 01/2016
2	nimotuzumabIBA 08/2017 - 02/2017
2	Lamivudine (Epivir)FDA Link 01/2016 - 12/2003
2	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2016 - 12/2003
2	Dexamethasone (Maxidex)FDA LinkGeneric 12/2015 - 02/2011
2	Ondansetron (Zofran)FDA LinkGeneric 12/2015 - 01/2014
2	Vincristine (Oncovin)FDA LinkGeneric 02/2011 - 09/2010
2	Rituximab (Mabthera)FDA Link 09/2010 - 08/2010
2	Epidermal Growth Factor (EGF)IBA 09/2009 - 01/2004
2	Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric 06/2005 - 02/2005
1	IntegrinsIBA 07/2022
1	patritumab deruxtecanIBA 01/2022
1	Protein Kinases (Protein Kinase)IBA 01/2022
1	tyrosine receptor (receptor, tyrosine)IBA 01/2022
1	nazartinibIBA 01/2022

Therapy/Procedure

60	Drug Therapy (Chemotherapy) 01/2022 - 07/2002
36	Therapeutics 01/2022 - 11/2008
12	Radiotherapy 01/2020 - 07/2002
5	Stem Cell Transplantation 02/2011 - 08/2002
4	Adjuvant Chemotherapy 01/2022 - 07/2002
3	Immunotherapy 06/2021 - 02/2019
2	Chemoradiotherapy 08/2015 - 05/2005
2	Aftercare (After-Treatment) 09/2009 - 11/2008
2	Stents 07/2009 - 12/2003